Endo to buy generics maker Par Pharmaceutical for $8B

Endo International PLC has agreed to buy Par Pharmaceutical Holdings Inc. from private-equity firm TPG for about $8 billion in cash and stock, a deal that would help boost its generics business.

The combined company would have a generics business among the top five by U.S. sales, according to Endo.

Dow Jones Newswires reports Par has some 100 products, including oral solid and injectables. TPG took the company private in 2012 for about $1.9 billion.

Read more from Dow Jones Newswires.